pcos treatment with glp 1 Your Body Isn't Broken: How GLP-1 Medications Are Changing The Game For PCOS Renamed PMOS: Peptide Therapy
Description
Another ongoing phase II study is assessing the efficacy and safety of semaglutide monotherapy and combination regimens with cilofexor and/or firsocostat in 440 patients with biopsy-confirmed NASH-related compensated cirrhosis (NCT04971785)

In a 48-week, placebo-controlled phase-2 trial (338 participants) reported by Lilly, the highest dose achieved a mean weight reduction of 24.2% (about 57.8 lb) at the end of treatment

Baek, HM15211, a novel GLP-1/GIP/glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: a phase 1b/2a, multi-center, randomized, placebo-controlled trial, J

N., & Garry, P
6.2 cmCSF)

Why the FDA Moved So Aggressively The FDAs February 6 announcement wasnt just about one company
